Macro and Strategy Research - The US labor market shows signs of weakness, with August non-farm employment data falling short of expectations and previous months' figures revised downwards, indicating a potential deterioration trend [3][4] - In Europe, the European Central Bank remains confident about future inflation and economic growth, with market expectations for a rate cut before mid-2026 dropping below 50% [4] - Domestic exports in China have declined year-on-year due to high base effects from last year, but exports to non-US regions continue to perform better, which may influence future growth [4][7] - The PPI in China is expected to show a low recovery in September, while CPI growth is significantly affected by food and energy prices [4][7] Fixed Income Research - The yield curve has steepened, with the bond market under pressure due to a strong equity market and adjustments in redemption fees affecting market sentiment [8][9] - In the primary market, the issuance of interest rate bonds totaled 74, with a net financing amount of 45.2 billion yuan, indicating a gradual decrease in supply pressure [7][9] - The central bank's actions, including potential 14-day reverse repos, will be crucial in determining the liquidity situation in the market [9] Industry Research - Chinese pharmaceutical companies showcased impressive research results at the World Lung Cancer Conference (WCLC), highlighting the strength of domestic innovation [10][12] - Hengrui Medicine has signed a licensing agreement for the HRS-1893 project and has received drug registration approval, indicating its ongoing expansion efforts [11][12] - The overall performance of the pharmaceutical and biotechnology sector has been positive, with the industry index showing a 1.76% increase, outperforming other sectors [11][12] - The upcoming China Clinical Oncology Society (CSCO) annual meeting and the European Society for Medical Oncology (ESMO) conference are expected to provide further insights into the industry's development [12]

Core Viewpoint - The Hong Kong Stock Connect Innovation Drug ETF (520880) is experiencing strong performance and investor interest, with significant inflows and a focus on innovative drug development companies [1][3]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovation Drug ETF (520880) has seen a trading volume exceeding 2.3 billion CNY, with a total inflow of over 5.1 billion CNY in the past week [1]. - The ETF is currently trading at a price of 0.653 CNY, reflecting a slight increase of 0.62% [2]. - The ETF has been consistently trading at a premium, indicating strong demand from investors [1]. Group 2: Market Trends - The ETF's underlying index has been revised to exclude CXO companies, focusing solely on innovative drug development firms, which enhances its ability to reflect the performance of China's innovative pharmaceutical sector [3]. - Recent policy support, including the inclusion of HPV vaccines in the national immunization program, is expected to benefit the innovative drug industry [3]. - The core product of one of the ETF's constituent companies, Yaojie Ankang, has received approval for a Phase II trial, marking a significant advancement in its research and development efforts [3]. Group 3: Sector Analysis - Analysts from Guojin Securities and Industrial Securities express optimism about the innovative drug sector, noting that while there may be increased volatility, the overall upward trend remains intact [3]. - The innovative drug sector is expected to continue being a core focus within the pharmaceutical industry, with ongoing policy support anticipated to enhance global competitiveness and commercial profitability [3]. - The top ten weighted stocks in the ETF include major players such as China Biologic Products, BeiGene, and CSPC Pharmaceutical Group, indicating a strong representation of leading companies in the innovative drug space [4].

Summary of Conference Call Records Industry Overview - The pharmaceutical industry is currently undergoing an adjustment period, presenting a favorable opportunity for investment in innovative drug companies, particularly recommending Kangfang Biotech, which has seen its stock price reach new highs due to positive news [1][3] - The overall performance of the pharmaceutical sector has been relatively weak, especially in the latter half of the week, influenced by a report from the U.S. "Today Times," causing market sentiment fluctuations [2] Key Recommendations - Kangfang Biotech is highlighted as a strong investment opportunity, consistently achieving new stock price highs with each positive development [3] - BeiGene is also recommended as a leading pharmaceutical stock, with secondary recommendations for Enhua Pharmaceutical and Tibet Pharmaceutical, the latter showing significant growth potential [1][3] Impact of Legislation - The Biodefense Safety Act has had limited impact on the fundamentals of domestic direct sales companies, with leading firms like WuXi AppTec and Kanglong Chemical maintaining strong growth in the U.S. market [4][5] - Growth rates for these companies are expected to rebound significantly starting in the second half of 2024, with good growth anticipated in the first half of 2025 [4] Order Growth - Companies have reported substantial growth in their order backlog for the first half of the year, with Aimingke showing a 37.2% increase and WuXi Biologics nearing a 20% increase when excluding Merck's vaccine orders, indicating a robust industry foundation [4][5] Geopolitical Factors - The likelihood of the Trump administration's new BD policy being fully implemented is considered low, with the domestic innovative drug industry maintaining global competitiveness due to talent, research efficiency, and cost advantages [6] - Similar to the Biodefense Safety Act, the new BD policy may cause short-term stock price fluctuations but is not expected to have a substantial long-term impact on the fundamentals of the industry [6]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.04%, Green Power Environmental (01330) at 69.16%, and China Shenhua (01088) at 67.97% [1] - Alibaba-W (09988), Horizon Robotics-W (09660), and Ping An of China (02318) saw the largest increases in holding amounts over the last five trading days, with increases of +14.898 billion, +1.834 billion, and +1.420 billion respectively [1] - The companies with the largest decreases in holding amounts over the last five trading days include Pop Mart (09992) with a decrease of -2.561 billion, Xiaomi Group-W (01810) with -2.531 billion, and Kangfang Biotech (09926) with -0.911 billion [2] Group 1: Top Holding Ratios - China Telecom (00728) has a holding ratio of 72.04% with 10 billion shares [1] - Green Power Environmental (01330) has a holding ratio of 69.16% with 280 million shares [1] - China Shenhua (01088) has a holding ratio of 67.97% with 2.296 billion shares [1] Group 2: Recent Increases in Holdings - Alibaba-W (09988) increased its holdings by +14.898 billion, adding 98.598 million shares [1] - Horizon Robotics-W (09660) increased its holdings by +1.834 billion, adding 17.948 million shares [1] - Ping An of China (02318) increased its holdings by +1.420 billion, adding 24.8703 million shares [1] Group 3: Recent Decreases in Holdings - Pop Mart (09992) decreased its holdings by -2.561 billion, reducing 9.2515 million shares [2] - Xiaomi Group-W (01810) decreased its holdings by -2.531 billion, reducing 45.9018 million shares [2] - Kangfang Biotech (09926) decreased its holdings by -0.911 billion, reducing 6.7244 million shares [2]

Group 1 - Alibaba-W (09988), Laopu Gold (06181), and China Pacific Insurance (02601) ranked the top three in net inflow of southbound funds, with net inflows of 4.484 billion, 463 million, and 456 million respectively [1][2] - Pop Mart (09992), Kangfang Biotech (09926), and Xiaomi Group-W (01810) ranked the top three in net outflow of southbound funds, with net outflows of -1.721 billion, -908 million, and -438 million respectively [1][2] - In terms of net inflow ratio, Tehai International (09658), Swire Properties B (00087), and Modern Dairy (01117) led the market with ratios of 60.71%, 57.33%, and 54.43% respectively [1][2] Group 2 - The top ten stocks by net inflow included Alibaba-W (09988) with 4.484 billion and a closing price of 142.800 (+0.63%), Laopu Gold (06181) with 463 million and a closing price of 755.000 (-7.59%), and China Pacific Insurance (02601) with 456 million and a closing price of 32.200 (+2.81%) [2] - The top ten stocks by net outflow included Pop Mart (09992) with -1.721 billion and a closing price of 275.200 (-4.51%), Kangfang Biotech (09926) with -908 million and a closing price of 133.500 (-4.71%), and Xiaomi Group-W (01810) with -438 million and a closing price of 54.950 (-2.22%) [2] - The top three stocks by net outflow ratio were Zhongjiao Holdings (00839) with -69.56%, Qingdao Bank (03866) with -60.56%, and Canggang Railway (02169) with -56.33% [3]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The 2025 World Conference on Lung Cancer (WCLC) highlighted the promising clinical data of domestic lung cancer drugs, particularly the innovative drug iza-bren developed by BaiLi Tianheng, which demonstrated a 100% objective response rate (ORR) in first-line patients with EGFR mutation non-small cell lung cancer (NSCLC) [2][17] - The report suggests a favorable outlook for the pharmaceutical sector, particularly in innovative drugs, research services, and CXO [3][12] Summary by Sections Industry Performance - The A-share pharmaceutical index has seen a year-to-date increase of 26.8%, while the Hang Seng Biotechnology Index has surged by 103.3% [11] - Notable stock performances include Zhend Medical (+41.3%) and Haooubo (+28.0%), while Yuekang Pharmaceutical (-18.4%) and Maiwei Biological (-14.4%) faced significant declines [11] New Drug Developments - Novartis' lung cancer drug, Capmatinib, received approval for a new indication in China, and Johnson & Johnson initiated a Phase III clinical trial for its KLK2/CD3 dual antibody [2] - BaiLi Tianheng's iza-bren showed a 100% ORR in a Phase II study for EGFR mutation NSCLC, with a median progression-free survival (mPFS) of 12.5 months [17][21] Investment Recommendations - The report ranks preferred sub-sectors as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [3][12] - Specific companies to watch include: - From GLP-1 perspective: BoRui Pharmaceutical, GeLi Pharmaceutical, and XinDa Biologics - From PD-1/VEGF dual antibody perspective: Kangfang Biologics and Shenzhou Cell - From AI drug development perspective: JingTai Holdings and Chengdu XianDao [3][12] Clinical Research Updates - The HARMONi study by Kangfang Biologics showed improved overall survival (OS) with a hazard ratio (HR) of 0.78, indicating a significant benefit for patients, especially in North America [25] - The report emphasizes the ongoing clinical trials for innovative drugs, including the registration Phase III study for iza-bren [20][24]

Group 1 - The core viewpoint of the news is that the innovative drug sector is experiencing a significant rebound, with both A-share and H-share innovative drug ETFs showing strong performance, indicating a bullish sentiment in the market [1][3][6] - The Hong Kong Stock Connect innovative drug ETF (520880) has seen a premium trading throughout the day, reflecting strong capital inflow, with over 160 million yuan invested during recent dips, marking eight consecutive days of capital accumulation [1][3] - Major stocks within the Hong Kong Stock Connect innovative drug ETF have collectively rebounded, with notable gains from companies such as Kangfang Biotech, which rose over 6%, and others like Innovent Biologics and CSPC Pharmaceutical, which increased by over 2% [3][4] Group 2 - The recent performance of the innovative drug ETF (520880) is attributed to a strategic adjustment in its underlying index, which now excludes CXO companies and focuses solely on innovative drug research and development, enhancing its ability to reflect industry trends accurately [5][6] - China's position in global new drug research has improved, with over 20% of new drugs in development worldwide originating from the country, highlighting the potential for continued growth in the innovative drug sector [6] - The low valuation of the Hong Kong innovative drug sector, combined with a high number of business development deals and ongoing interest in areas like small nucleic acids and oral GLP-1, suggests strong future growth potential [6]

Group 1 - The Hong Kong stock market showed strong performance from September 8 to September 12, with the Hang Seng Index rising by 3.82% to 26,388.16 points, marking the highest level since September 2021 [4][5] - The Hang Seng Technology Index increased by 5.31%, while the Hang Seng China Enterprises Index rose by 3.40% [4] - Among the ten sectors in the Hong Kong market, all but the healthcare sector saw gains, with real estate, information technology, and materials leading the way with increases of 6.56%, 6.08%, and 5.71% respectively [5][12] Group 2 - The average daily trading volume on the Hong Kong Stock Exchange was HKD 303.03 billion, a decrease of HKD 12.76 billion from the previous week [12] - Southbound capital saw a net inflow of HKD 60.82 billion, an increase of HKD 27.76 billion compared to the previous week [12] - The short-selling amount averaged HKD 34.40 billion, which accounted for 11.38% of the trading volume, an increase of 0.24 percentage points from the previous week [12] Group 3 - As of September 12, the price-to-earnings (PE) and price-to-book (PB) ratios for the Hang Seng Index were 12.04 times and 1.23 times, respectively, reflecting increases of 4.7% and 4.47% from the previous week [17] - The Hang Seng Technology Index had a PE ratio of 23.12 times and a PB ratio of 3.38 times, indicating that it is positioned at the 31% and 73% percentile levels since 2019 [17] - The risk premium for the Hang Seng Index was calculated at 4.25%, which is at the 5% percentile level since 2010 [20][26] Group 4 - The report highlights potential investment opportunities in sectors with high earnings growth but relatively low valuations, such as consumer discretionary and healthcare [40] - It also suggests focusing on sectors benefiting from favorable policies, such as the AI industry chain and consumer sectors [40] - Financial sectors with high dividend yields are expected to provide stable returns amid uncertainties [40]

Investment Rating - The industry rating is "stronger than the market" indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 months [6][75]. Core Insights - The report analyzes the impact of the "Biological Safety Act" on the CXO industry and concludes that the BD policies will not have a substantial effect on the innovative drug sector [4][28]. - The CXO companies have shown resilience, with stock prices recovering and reaching new highs despite the changes in the Biological Safety Act [4][17]. - The report emphasizes the advantages of China's innovative drug industry, including talent resources, research efficiency, and cost-effectiveness, which are expected to mitigate the impact of external policies [4][28]. Summary by Sections Market Review - During the week of September 8-12, 2025, the CITIC Pharmaceutical Index fell by 0.3%, underperforming the CSI 300 Index by 1.7 percentage points, ranking 28th among CITIC's primary industry classifications [3][30]. - Year-to-date, the CITIC Pharmaceutical and Biotechnology Index has risen by 27.8%, outperforming the CSI 300 Index by 12.9 percentage points, ranking 8th among CITIC's industry classifications [3][30]. - The top five performing stocks for the week included: Zhend Medical (+41.3%), Haooubo (+28%), Jimin Medical (+25.9%), Kangwei Century (+23.2%), and Ao Jing Medical (+20.5%) [3][44]. Impact of the Biological Safety Act - The report details the evolution of the Biological Safety Act since December 30, 2023, noting that the stock price reactions of representative CXO companies have become desensitized over time, with current prices surpassing levels from December 29, 2023 [4][17]. - The performance of CXO companies in the U.S. market has remained strong, with significant growth in orders and revenue despite the act's implications [24][28]. Investment Focus - The report suggests focusing on three main areas in the innovative drug and its supply chain: companies with revenue and commercialization capabilities, potential BD opportunities based on technological trends, and exploring cutting-edge technologies such as gene therapy and CAR-T [5][28]. - The medical device sector is also highlighted as a key area for investment, with expectations of a policy turning point and improving fundamentals [5][28]. Stock Recommendations - The report recommends a focus on specific stocks including Kangfang Biotech, Baiji Shenzhou, Xinda Biotech, Enhua Pharmaceutical, and others for the upcoming month [5][12].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [6] Core Insights - The report highlights the promising clinical data of BaiLi Tianheng's EGFR/HER3 dual antibody ADC, iza-bren, for treating EGFR mutation lung cancer, which shows potential for further clinical advancement [2][3][20][21][23] Summary by Sections Weekly New Drug Market Review - From September 8 to September 14, 2025, the top five gainers in the new drug sector were: - Saintno Pharmaceutical (+32.00%) - Junshengtai (+23.73%) - Canaan Bio (+20.43%) - Rongchang Bio (+16.52%) - Hengrui Medicine (+11.91%) - The top five losers were: - Basestone Pharmaceuticals (-18.90%) - Laika Pharmaceuticals (-18.12%) - Gilead Sciences (-16.93%) - Maiwei Bio (-14.41%) - Yifang Bio (-12.46%) [1][15] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences, business development realizations, and insurance negotiations. Key stocks to watch include: 1. Potential overseas licensed MNC heavyweights: - Differentiated GLP-1 assets: Zhongsheng Pharmaceutical, Gilead Sciences, Borui Pharmaceutical, Kangyuan Pharmaceutical - Upgraded PD-1 products: Kangfang Bio and other PD-1/VEGF assets, Innovent Biologics - Breakthroughs in autoimmune fields: Yifang Bio, China Antibody - Innovative target ADCs: Fuhong Hanlin, Shiyao Group 2. MNC-certified products with high overseas volume certainty: - Upgraded PD-1 products: Sanofi Pharmaceutical - GLP-1 assets: Lianbang Pharmaceutical - ADC assets: Kelong Botai, BaiLi Tianheng 3. Products likely to benefit from insurance negotiations and innovative drug directories [2][20] New Drug Industry Focus Analysis - At the recent 2025 World Lung Cancer Conference (WCLC), BaiLi Tianheng presented results from two studies on its EGFR×HER3 dual antibody ADC, iza-bren, showing excellent clinical data in both first-line and second-line treatments for advanced or metastatic EGFR mutation NSCLC. The results indicate a promising future for its application in relevant indications [2][20][21] New Drug Approval and Acceptance Status - No new drug or new indication applications were approved this week, but seven new drug or new indication applications were accepted [3][25] Clinical Application Approval and Acceptance Status - This week, 41 new drug clinical applications were approved, and 46 new drug clinical applications were accepted [9][28]